Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Psychother Psychosom Med Psychol ; 63(9-10): 381-6, 2013 Sep.
Artigo em Alemão | MEDLINE | ID: mdl-23592491

RESUMO

The surgical treatment of uterine fibroids represents an important column in the therapy of this disease. Aim of this study was to find out preoperative factors that influence the treatment success of a minimal-invasive surgical -therapy.In a retrospective study 228 patients were assessed. Measures comprised questions on the decision for surgery, satisfaction with the treatment, and the EQ-5D as a measure of QoL.The sample revealed an overall satisfaction with treatment and high QoL. A better postoperative contentment and QoL in patients who felt well informed about the surgical methods and who felt secure with their decision for a specific surgery was found.Regardless of the surgical method, the preoperative consultation and the certainty of the decision turned out to be determinants of the patients' postoperative contentment and QoL. The counseling gynecologist has an essential part in the patients' decision for the treatment.


Assuntos
Procedimentos Cirúrgicos em Ginecologia/psicologia , Histerectomia/psicologia , Consentimento Livre e Esclarecido/psicologia , Leiomioma/cirurgia , Satisfação do Paciente , Qualidade de Vida , Adulto , Idoso , Feminino , Procedimentos Cirúrgicos em Ginecologia/efeitos adversos , Humanos , Histerectomia/efeitos adversos , Leiomioma/psicologia , Pessoa de Meia-Idade , Período Pós-Operatório , Cuidados Pré-Operatórios , Resultado do Tratamento
2.
Eur J Obstet Gynecol Reprod Biol ; 162(2): 192-6, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22445108

RESUMO

OBJECTIVE: Women in the peri- and post-menopause may ask for uterus-preserving therapy options when presenting with benign uterine disorders such as symptomatic fibroids. Laparoscopic myomectomy (LM) for patients in the peri- and post-menopause as a surgical alternative to hysterectomy is widely considered to be non-standard treatment. The aim of this study was to analyze safety and outcome of LM beyond the reproductive period. STUDY DESIGN: We evaluated the surgical outcome and patient satisfaction for a total of 451 patients: 85 peri- or post-menopausal women as group A and, for reference, 366 premenopausal women in group B, who received LM from 1998 to 2008 in our department. We analyzed data from our medical records and applied a patient questionnaire in September 2009. RESULTS: The average number of fibroids removed and size of the leading fibroid were similar in both groups. Time of surgery was different in group A, at 102.8 min, compared to group B, 128.6 min (p<0.01). Rates of intra- (2.21% overall) and post-operative complications (6.22% overall) were comparable for both groups. Post-surgical hospitalization was shorter in group B (4.4 days) compared to group A (5.0 days) (p<0.01). Evaluation of the questionnaire showed high satisfaction with the results of LM in both subgroups with a significantly lower number of relapses in group A (3.5%) compared to group B (11.2%). CONCLUSION: Laparoscopic myomectomy as a surgical treatment option in the peri- and post-menopause was characterized by a low rate of complications and relapses as well as a high degree of patient satisfaction in our analysis.


Assuntos
Procedimentos Cirúrgicos em Ginecologia/estatística & dados numéricos , Leiomioma/cirurgia , Perimenopausa , Pós-Menopausa , Neoplasias Uterinas/cirurgia , Adulto , Feminino , Humanos , Laparoscopia , Pessoa de Meia-Idade , Miométrio/cirurgia , Satisfação do Paciente/estatística & dados numéricos
3.
Int J Gynecol Cancer ; 21(8): 1399-406, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21897273

RESUMO

OBJECTIVE: Hereditary epithelial ovarian cancers (EOCs) not expressing functional BRCA1 protein are characterized by defects in homologous recombination DNA repair, rendering such tumors more sensitive to DNA damaging agents and synthetic lethality, that is, poly-ADP-ribose-polymerase inhibitor treatment. The aim of this study was to evaluate the use of BRCA1 immunohistochemistry (IHC) for EOC prognosis and identification of features of the BRCAness phenotype. METHODS: Twenty-seven patients who were treated for advanced EOC by macroscopic complete surgical tumor resection and first-line carboplatin/paclitaxel treatment were included. Time to recurrence and overall survival time after initial surgery were determined, and patients' samples were evaluated for BRCA1 expression by IHC. BRCA1 messenger RNA expression and promoter methylation was analyzed to elucidate regulatory mechanisms involved in BRCA1 protein loss. RESULTS: BRCA1 IHC-negative patients had a significantly longer overall survival (crude rate, 1537 days) compared to the BRCA1 IHC-positive group (crude rate, 827 days; P = 0.01). The patients in the BRCA1 IHC-negative group were significantly younger (51 years) compared to BRCA1 IHC-positive patients (61 years; P < 0.01). Importantly, both transcriptional and posttranscriptional mechanisms regulate BRCA1 protein expression. Only protein but not messenger RNA level were associated with longer overall survival. CONCLUSION: Epithelial ovarian cancers with negative BRCA1 protein expression were identified in younger patients, showed a significantly better overall survival, prolonged treatment intervals and a tendency for an extended progression free time interval. BRCA1 IHC negativity of sporadic EOC may be predictive of sensitivity to platinum-based chemotherapy and the poly-ADP-ribose-polymerase inhibitor-sensitive BRCAness phenotype.


Assuntos
Adenocarcinoma/metabolismo , Proteína BRCA1/metabolismo , Biomarcadores Tumorais/metabolismo , Neoplasias Ovarianas/metabolismo , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/mortalidade , Adulto , Idoso , Antineoplásicos/uso terapêutico , Carboplatina/uso terapêutico , Feminino , Alemanha/epidemiologia , Humanos , Imuno-Histoquímica , Pessoa de Meia-Idade , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/mortalidade , Paclitaxel/uso terapêutico , Fenótipo , Estudos Retrospectivos
5.
Int J Gynecol Cancer ; 21(6): 1056-62, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21633301

RESUMO

OBJECTIVE: Assessment of adnexal masses focuses on the accurate discrimination between benign and malignant lesions. In our tertiary referral center, we evaluated the discriminative power of expert sonography, serum CA-125 measurement, risk malignancy index (RMI) by Jacobs, and 2 preoperative triage strategies (combination of CA-125 measurement and RMI assessment with expert sonography). METHODS: From 2002 to 2008, a total of 1362 surgical explorations with indication of an adnexal mass from our department were included in this study. Preoperative workup in all patients comprised a gynecologic examination, expert sonography, and serum CA-125 measurement. We calculated sensitivity, specificity, positive and negative predictive value (PPV and NPV), and Cohen κ (prevalence-adjusted measurement) to evaluate the discriminative power of each diagnostic test. RESULTS: Discriminative power of the evaluated tests differed depending on patients' menopausal state. In the premenopause, expert sonography reached the highest discriminative power with a κ value of 0.53, a PPV of 0.45, and an NPV of 0.99. In the postmemopause, the combinations of expert sonography with CA-125 serum measurement or RMI assessment achieved the highest discriminative power: The combination of CA-125 and expert sonography reached a PPV of 0.89 and an NPV of 0.97; κ yielded 0.84. The RMI combined with expert sonography as a triage strategy showed comparable results with a PPV of 0.89, an NPV of 0.96, and a κ value of 0.82. CONCLUSIONS: Preoperative assessment of an adnexal mass may be guided by the patient's menopausal state. In premenopausal patients, expert sonography is helpful for preoperative differentiation between benign and malignant lesions; in postmenopausal patients, the use of triage strategies of either CA-125 serum measurement or RMI combined with expert sonography can be recommended.


Assuntos
Doenças dos Anexos/diagnóstico , Doenças dos Anexos/sangue , Doenças dos Anexos/diagnóstico por imagem , Doenças dos Anexos/patologia , Doenças dos Anexos/terapia , Adulto , Antígeno Ca-125/sangue , Terapia Combinada , Feminino , Alemanha , Humanos , Laparoscopia , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Ambulatório Hospitalar , Valor Preditivo dos Testes , Período Pré-Operatório , Medição de Risco , Sensibilidade e Especificidade , Triagem , Ultrassonografia
6.
Chem Immunol Allergy ; 89: 26-35, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16129950

RESUMO

Pregnancy is accompanied by a Th2-prone immune modulation, which is a major puzzle piece among maternofetal tolerance-promoting factors. A large number of cytokines is physiologically or pathologically present in the decidua and is potentially able to act on lymphocytes and NK cells, which express a variety of respective receptors. Intracellular signals from these receptors are to a major part transduced via the Janus kinases (JAK) and signal transducers and activators of a transcription (STAT) system, which consists of at least 4 different kinases and 7 STATs plus several subtypes and splicing variants. A network of suppressors of cytokine signaling (SOCS) controls their balance. The interactions of all these intracellular factors and cross-linking with further signaling systems seem to be crucial for the maintenance of a maternal cytokine profile which promotes the tolerance of the fetus.


Assuntos
Linfócitos/imunologia , Linfócitos/metabolismo , Troca Materno-Fetal/imunologia , Animais , Citocinas/metabolismo , Decídua/imunologia , Decídua/metabolismo , Feminino , Substâncias de Crescimento/metabolismo , Humanos , Células Matadoras Naturais/imunologia , Células Matadoras Naturais/metabolismo , Gravidez , Proteínas Tirosina Quinases/imunologia , Transdução de Sinais , Linfócitos T/imunologia , Linfócitos T/metabolismo , Transativadores/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...